Lilly drug combo shows superior results in psoriatic arthritis study
Tweet Send to a Friend
Eli Lilly and Company (NYSE: LLY) reported that its combination therapy of Taltz and Zepbound demonstrated superior efficacy compared to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


